{"id":55365,"date":"2023-03-30T16:06:34","date_gmt":"2023-03-30T14:06:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/"},"modified":"2023-03-30T16:06:34","modified_gmt":"2023-03-30T14:06:34","slug":"mytide-therapeutics-announces-leadership-transition","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/","title":{"rendered":"Mytide Therapeutics Announces Leadership Transition"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–Mytide, the tech-enabled biotechnology manufacturing services company, today announced the appointment of Dr. Martina Diekmann as Chief Executive Officer. She will take over as CEO from Mytide\u2019s founder Dale Thomas, who has served as the company\u2019s CEO since 2018.\n<\/p>\n

<\/a><\/p>\n

\nFollowing Dr. Diekmann\u2019s appointment, Thomas will assume the role of Chief Technology Officer and focus on driving future innovation. Thomas has been instrumental in establishing Mytide, known for its innovative automated peptide manufacturing platform that combines machine learning\/AI with robotic systems. In transitioning to the CTO role, Thomas will fully focus on the company\u2019s continued innovation and further technological development. This decision was made to support Mytide\u2019s strong growth and leverage its proprietary technology into new applications.\n<\/p>\n

\nDr. Diekmann joined Mytide\u2019s Advisory Board in November 2022. Since then, she has been a strategic advisor to Mytide and worked alongside Dale Thomas ever since. Martina Diekmann has previously held several senior executive roles with high growth CRO\/CDMO businesses in the life science sector. Most recently she served as CEO of vivitide, a supplier of custom peptides, antibodies and proteomic tools. Prior to that she held management positions at Bachem AG and Solvias AG. Her expertise will be instrumental in driving Mytide’s growth as the company transitions from technology development into production and revenue growth.\n<\/p>\n

\n\u201cMytide is building a new 10,000-square-foot production facility in Waltham, which will house our second-generation Biopolymer Fabrication (BioFab) platforms. The build out allows us to scale the manufacturing of peptides throughout 2023\/2024 to meet demand,\u201d said Dr. Diekmann. \u201cWe are currently enrolling new clients in our membership program that has been designed to grant access to the fastest turn-around peptide manufacturing platform on the market,\u201d added Dale Thomas. “It has been proven to provide rapid access to peptides for some of the most exciting drug discovery and biology pipelines, particularly within neoantigen, cell therapy, and vaccine development.\u201d\n<\/p>\n

\n“We are thrilled to have Martina join Mytide\u2019s team as CEO and to have Dale transition into the role of CTO,” said Errik Anderson, Alloy Therapeutics CEO and member of Mytide\u2019s Board of Directors. “Mytide\u2019s leadership team is now well positioned to accelerate the company\u2019s growth plans and ensure Mytide will continue to be at the forefront of innovation in the biotechnology manufacturing services sector.”\n<\/p>\n

\nAbout Mytide\n<\/p>\n

\nMytide is a tech-enabled biotechnology manufacturing services company focused on the production of peptides for drug discovery and development. Mytide’s mission is to provide rapid access to high-quality peptides through its innovative ecosystem, which includes a rapid turn-around peptide membership services program. For more information, visit www.mytide.io<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMartina (Tina) Diekmann
\n
martina@mytide.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Mytide, the tech-enabled biotechnology manufacturing services company, today announced the appointment of Dr. Martina Diekmann as Chief Executive Officer. She will take over as CEO from Mytide\u2019s founder Dale Thomas, who has served as the company\u2019s CEO since 2018. Following Dr. Diekmann\u2019s appointment, Thomas will assume the role of Chief Technology Officer and focus … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55365","6":"format-standard","7":"category-industry"},"yoast_head":"\nMytide Therapeutics Announces Leadership Transition - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mytide Therapeutics Announces Leadership Transition - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–Mytide, the tech-enabled biotechnology manufacturing services company, today announced the appointment of Dr. Martina Diekmann as Chief Executive Officer. She will take over as CEO from Mytide\u2019s founder Dale Thomas, who has served as the company\u2019s CEO since 2018. Following Dr. Diekmann\u2019s appointment, Thomas will assume the role of Chief Technology Officer and focus ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T14:06:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mytide Therapeutics Announces Leadership Transition\",\"datePublished\":\"2023-03-30T14:06:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/\"},\"wordCount\":451,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005266\\\/en\\\/1751684\\\/21\\\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/\",\"name\":\"Mytide Therapeutics Announces Leadership Transition - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005266\\\/en\\\/1751684\\\/21\\\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg\",\"datePublished\":\"2023-03-30T14:06:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005266\\\/en\\\/1751684\\\/21\\\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005266\\\/en\\\/1751684\\\/21\\\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mytide-therapeutics-announces-leadership-transition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mytide Therapeutics Announces Leadership Transition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mytide Therapeutics Announces Leadership Transition - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/","og_locale":"en_US","og_type":"article","og_title":"Mytide Therapeutics Announces Leadership Transition - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–Mytide, the tech-enabled biotechnology manufacturing services company, today announced the appointment of Dr. Martina Diekmann as Chief Executive Officer. She will take over as CEO from Mytide\u2019s founder Dale Thomas, who has served as the company\u2019s CEO since 2018. Following Dr. Diekmann\u2019s appointment, Thomas will assume the role of Chief Technology Officer and focus ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-30T14:06:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mytide Therapeutics Announces Leadership Transition","datePublished":"2023-03-30T14:06:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/"},"wordCount":451,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/","url":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/","name":"Mytide Therapeutics Announces Leadership Transition - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg","datePublished":"2023-03-30T14:06:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005266\/en\/1751684\/21\/Screen_Shot_2023-03-29_at_8.09.21_PM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mytide-therapeutics-announces-leadership-transition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mytide Therapeutics Announces Leadership Transition"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55365"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55365\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}